PR Newswire Clinical TrialsOriginal article
Ceramedix Awarded Up to $4.5 Million NIAID Contract to Advance Lead GI-ARS Therapeutic Toward IND Submission
PartnershipGI-ARS TherapeuticPositive
AI Analysis
Summary
Ceramedix received a multi-year contract of up to $4.5 million from NIAID's Radiation and Nuclear Countermeasures Program to advance its GI-ARS therapeutic candidate toward IND submission.
Outcome Details
Multi-year contract awarded for therapeutic development
Importance:6/10
Sentiment:
0.70
government fundingcontract awardIND submissionrare diseaseNIAID
Related Companies
Read the original article
Published by PR Newswire Clinical Trials on August 11, 2026 12:31 PM